Myasthenia gravis: vizsgálatok itt: Görögország
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Athens, Chaïdári, Larissa, Patras
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - 3. fázisTaking peopleA Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Athens, Chaïdári, Larissa, Patras
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00 - 2. fázisTaking peopleADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Where
- Athens, Thessaloniki
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00 - No phaseTaking peopleADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Where
- Athens, Thessaloniki
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07294170 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Larissa, Patras, Thessaloniki
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 2. fázisTaking peopleADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Where
- Athens, Thessaloniki
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Where
- Athens, Chaïdári, Patras, Thessaloniki
- Életkor
- 18 év to 80 év
- People
- 231 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00